Key Highlights

  • Share price up today, market capitalisation in the multi‑billion range · Next catalyst: second‑half results
  • Swedencare reported Q2 earnings per share below consensus estimates.
  • Total organic growth reached 7%.
  • Operational EBITDA amounted to SEK 129.4 million, representing a 19.3 % margin.
  • Production segment posted strong organic growth of 25 %, while North America was down 3 %.

Swedencare AB (publ) (OTC: SWDCF) saw its shares climb noticeably in recent trading, even though the company missed earnings‑per‑share expectations for the most recent quarter. The miss highlighted a gap between analyst forecasts and actual profitability, yet the market response emphasized the firm’s underlying growth dynamics and cash generation capability, which were underscored during the earnings discussion.

Financial Overview Highlights Resilience

The quarter delivered a mixed financial picture. Organic growth for the period was recorded at 7%, a rate the company described as resilient given broader market pressures. Operational EBITDA, which the firm equates with ordinary EBITDA, stood at SEK 129.4 million, delivering a margin of 19.3 %.

This metric signals solid earnings from core operations. The combination of stable margins and stronger cash flow reflects the company’s ability to sustain its investment in the pet‑care sector.

Regional Performance Shows Divergence

Swedencare’s geographical and operational segments displayed varying trends. The Europe segment continued to expand robustly, benefiting from favorable market conditions and product uptake. The Production segment was particularly strong, achieving organic growth of 25 %, indicating efficient manufacturing and effective demand generation.

Conversely, the North America segment experienced a contraction, with organic growth down 3 %. Management attributed the slowdown to temporary disruptions and delays in product introductions within the U.S. veterinary channel, and expects a rebound later in the year as those initiatives gain momentum.

Management Outlook Emphasises Recovery and Growth

During the earnings call, CEO Hakan Lagerberg and CFO Jenny Graflind reiterated confidence in the company’s strategic direction. They highlighted the resilient performance across European markets and the production base, while acknowledging the short‑term challenges in North America. The leadership team conveyed optimism that the upcoming initiatives will revive growth in the North American market during the second half of the year.

Geoff Granger, CEO of NaturVet, also participated in the discussion, hinting at potential collaborative opportunities that could further strengthen Swedencare’s market position.

Investor Sentiment Focuses on Operational Strength

The share price uplift following the earnings release suggests investors are placing greater weight on the company’s operational fundamentals and growth trajectory rather than the short‑term earnings miss. Market participants appear to value the solid European and production segment performance and the anticipated recovery in North America as key drivers for future value creation. This sentiment, coupled with the firm’s strong cash generation, positions Swedencare favorably as it navigates the remainder of the fiscal year.

Based on Swedencare AB's Q2 2026 Earnings Call Transcript.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.